Business
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
BERLIN & NAPLES, Fla., January 12, 2026--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac a
About this update from Bayer Ag
[{"type":"text","content":"Not intended for UK Media","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis for cardiac amyloidosis","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"PET tracer AT-01 in Phase III and SPECT tracer AT-05 in Phase I of clinical development specifically designed for the diagnosis of cardiac as well as other types of systemic amyloidosis","length":185,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Potential to address the growing need for earlier and accurate diagnosis of these often underdiagnosed conditions","length":113,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AT-01 (124-Iodine-evuzamitide) is first pan-amyloid imaging agent with U.S. FDA Breakthrough Therapy Designation for cardiac amyloidosis; AT-01 also holds Orphan Drug Designation in U.S. and EU","length":193,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Building on its comprehensive radiology portfolio including advanced fluid delivery devices in molecular imaging, Bayer reinforces its ambition to expand in this rapidly growing field by entering the area of diagnostic tracers, while bolstering its position in cardiovascular precision medicine","length":294,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Attralus will now focus on advancing its innovative pan-amyloid removal therapeutics, with AT-02 in Phase II and next generation candidates in preclinical development","length":166,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1123,"olType":false},{"type":"text","content":"BERLIN & NAPLES, Fla., January 12, 2026--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from Attralus. This strategic acquisition reinforces Bayer’s ambition ...